RNA interference mediated inhibition of cyclin dependent kinase-2 (CDK2) gene expression using short interfering nucleic acid (siNA)
AssigneeSirna Therapeutics, Inc.
InventorJames McSwiggen
Life of this patent
Estimating the term…
Loading patent…
AssigneeSirna Therapeutics, Inc.
InventorJames McSwiggen
Estimating the term…
This invention relates to compounds, compositions, and methods useful for modulating cyclin dependent kinase-2 (CDK2) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of CDK2 gene expression and/or activity by RNA interference (RNAi) using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules and methods used to modulate the expression of CDK2 genes.
A chemically synthesized double stranded short interfering nucleic acid (siNA) molecule that directs cleavage of a cyclin dependent kinase-2 (CDK2) RNA via RNA interference (RNAi), wherein:
Dependencies are inferred from the claim text.